One good thing is "The Licensing Agreement continues in full force and effect pending the
Arbitrator's decision". Even if POH doesn't get a big amount but retain the ownership of TPM®/Daptomycin injectable, Mylan will need to pay POH % royalties. Few % to POH vs delays/ not launching the product into huge daptomycin market is on POH side. Few % for POH will be big money, plus recognition and market exposure. I prefer $30M settlement in one month and % royalties than $50M in June 2018 and implicit a CR. IMO
Ann: Phosphagenics Market Update - Potential Return of Capital, page-53
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(50.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $52 | 21.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 6846739 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 41919123 | 29 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |